

IFW16

RAW SEQUENCE LISTING

DATE: 08/11/2004

PATENT APPLICATION: US/09/647,457D

TIME: 16:12:08

Input Set : A:\1276302-3corrected.ST25.txt Output Set: N:\CRF4\08112004\I647457D.raw

```
3 <110> APPLICANT: Yeda Research and Development Company Ltd.
      5 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW
      7 <130> FILE REFERENCE: 24390 (1276302)
      9 <140> CURRENT APPLICATION NUMBER: 09/647,457D
C--> 10 <141> CURRENT FILING DATE: 2000-11-29
     12 <150> PRIOR APPLICATION NUMBER: PCT/IL99/00190
     13 <151> PRIOR FILING DATE: 1999-09-29
     15 <150> PRIOR APPLICATION NUMBER: 123925
     16 <151> PRIOR FILING DATE: 1998-04-02
     18 <160> NUMBER OF SEQ ID NOS: 15
     20 <170> SOFTWARE: PatentIn version 3.2
     22 <210> SEQ ID NO: 1
     23 <211> LENGTH: 28
     24 <212> TYPE: PRT
     25 <213> ORGANISM: Unknown
     27 <220> FEATURE:
     28 <223> OTHER INFORMATION: being the immunologically active epitope
     31 <220> FEATURE:
     32 <221> NAME/KEY: MISC_FEATURE
     33 <222> LOCATION: (1)..(11)
     34 <223> OTHER INFORMATION: Xaa(1) is S or absent; Xaa(2) is G or absent; Xaa(3) is E or
              absent; Xaa(4) is T or absent; Xaa(5) is E or absent; Xaa(6) is
     35
     36
              D or absent; Xaa(7) is T or absent; Xaa(8) is F or absent;
     37
              Xaa(9) is 1 or absent; Xaa(10) is A or absent; provided that
W--> 38
             when Xaa(11) is absent, Xaa(1) through Xaa(10), inclusive, are
  -> 39
              absent, and when Xaa(11) is D , Xaa(10) is A or absent; when
              Xaa(10) is absent, Xaa(1) through Xaa(9), inclusive, are absent,
W--> 40
             and when Xaa(10) is A, Xaa(9) is I or absent; when Xaa(9) is
  -> 41
W--> 42
             absent, Xaa(1) through Xaa(8), inclusive, are absent, and when
W--> 43
              Xaa(9) is I, Xaa(8) is F or absent; when Xaa(8) is absent,
W--> 44
              Xaa(1) through Xaa(7), inclusive, are absent, and when Xaa(8) is
              F, Xaa(1) through Xaa(7) are, respectively, S, G, E, T, E, D,
W - - > 45
W--> 46
              and T.
    48 <220> FEATURE:
    49 <221> NAME/KEY: MISC FEATURE
    50 <222> LOCATION: (12)..(28)
    50 <2225 BOCATION: (12,...(25)
51 <223> OTHER INFORMATION: Xaa(19) is C, G, P; Xaa(25) is A, P; Xaa(26) is P, A; Xaa(28)
     52
              R or absent, provided that Xaa(25) and Xaa(26) are taken together
    53
              to form a sequence selected from the group consisting of AP and
     54
              PA.
     56 <400> SEQUENCE: 1
```

59 1 5 10 15

DATE: 08/11/2004

TIME: 16:12:08

```
Input Set : A:\1276302-3corrected.ST25.txt
                     Output Set: N:\CRF4\08112004\I647457D.raw
     62 Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Xaa Cys Xaa
     63
                    20
     66 <210> SEQ ID NO: 2
     67 <211> LENGTH: 28
     68 <212> TYPE: PRT
     69 <213> ORGANISM: Unknown
     71 <220> FEATURE:
     72 <223> OTHER INFORMATION: being the immunologically active epitope
     74 <400> SEQUENCE: 2
     76 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
     77 1
                        5
     80 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arq
     81
                    20
     84 <210> SEQ ID NO: 3
     85 <211> LENGTH: 16
     86 <212> TYPE: PRT
     87 <213> ORGANISM: Unknown
    89 <220> FEATURE:
     90 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     91
              levels in body fluids of schizophrenic patients.
     93 <400> SEQUENCE: 3
     95 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
     96 1
     99 <210> SEQ ID NO: 4
     100 <211> LENGTH: 20
     101 <212> TYPE: PRT
     102 <213> ORGANISM: Unknown
     104 <220> FEATURE:
     105 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
               levels in body fluids of schizophrenic patients.
     106
     108 <400> SEQUENCE: 4
     110 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
     111 1
     114 Ala Pro Cys Arg
     115
                     20
     118 <210> SEQ ID NO: 5
     119 <211> LENGTH: 19
     120 <212> TYPE: PRT
     121 <213> ORGANISM: Unknown
     123 <220> FEATURE:
     124 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
               levels in body fluids of schizophrenic patients
     127 <400> SEQUENCE: 5
    129 Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala
    130 1
                                              10
    133 Pro Cys Arg
    137 <210> SEQ ID NO: 6
    138 <211> LENGTH: 18
    139 <212> TYPE: PRT
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457D

DATE: 08/11/2004

## PATENT APPLICATION: US/09/647,457D TIME: 16:12:08 Input Set : A:\1276302-3corrected.ST25.txt Output Set: N:\CRF4\08112004\I647457D.raw 140 <213> ORGANISM: Unknown 142 <220> FEATURE: 143 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients 146 <400> SEQUENCE: 6 148 Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro 10 149 1 152 Cys Arg 156 <210> SEQ ID NO: 7 157 <211> LENGTH: 17 158 <212> TYPE: PRT 159 <213> ORGANISM: Unknown 161 <220> FEATURE: 162 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients 163 165 <400> SEQUENCE: 7 167 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys 168 1 5 1.0 171 Arg 175 <210> SEQ ID NO: 8 176 <211> LENGTH: 17 177 <212> TYPE: PRT 178 <213> ORGANISM: Unknown 180 <220> FEATURE: 181 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients 184 <400> SEQUENCE: 8 186 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys 187 1 5 190 Arg 194 <210> SEQ ID NO: 9 195 <211> LENGTH: 17 196 <212> TYPE: PRT 197 <213> ORGANISM: Unknown 199 <220> FEATURE: 200 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients 203 <400> SEQUENCE: 9 205 Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys 10 206 1 209 Arg 213 <210> SEQ ID NO: 10 214 <211> LENGTH: 20 215 <212> TYPE: PRT 216 <213> ORGANISM: Unknown

219 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in

levels in body fluids of schizophrenic patients

RAW SEQUENCE LISTING

218 <220> FEATURE:

elevated

220

222 <400> SEQUENCE: 10

DATE: 08/11/2004

```
PATENT APPLICATION: US/09/647,457D
                                                               TIME: 16:12:08
                     Input Set : A:\1276302-3corrected.ST25.txt
                     Output Set: N:\CRF4\08112004\I647457D.raw
     224 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
     225 1
                                              10
     228 Cys Thr Gly Gln
                     20
     229
     232 <210> SEQ ID NO: 11
     233 <211> LENGTH: 16
     234 <212> TYPE: PRT
     235 <213> ORGANISM: Unknown
     237 <220> FEATURE:
     238 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
               levels in body fluids of schizophrenic patients
     241 <400> SEQUENCE: 11
     243 Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
     244 1
     247 <210> SEQ ID NO: 12
     248 <211> LENGTH: 12
     249 <212> TYPE: PRT
     250 <213> ORGANISM: Unknown
    252 <220> FEATURE:
     253 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     254
               levels in body fluids of schizophrenic patients
     256 <400> SEQUENCE: 12
     258 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
     259 1
     262 <210> SEQ ID NO: 13
     263 <211> LENGTH: 16
     264 <212> TYPE: PRT
     265 <213> ORGANISM: Unknown
    267 <220> FEATURE:
     268 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     269
               levels in body fluids of schizophrenic patients
     271 <400> SEQUENCE: 13
     273 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
    277 <210> SEQ ID NO: 14
     278 <211> LENGTH: 15
    279 <212> TYPE: PRT
     280 <213> ORGANISM: Unknown
    282 <220> FEATURE:
    283 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
               levels in body fluids of schizophrenic patients
    286 <400> SEQUENCE: 14
    288 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
    292 <210> SEQ ID NO: 15
    293 <211> LENGTH: 16
    294 <212> TYPE: PRT
    295 <213> ORGANISM: Unknown
    297 <220> FEATURE:
```

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING

DATE: 08/11/2004

PATENT APPLICATION: US/09/647,457D

TIME: 16:12:08

Input Set : A:\1276302-3corrected.ST25.txt Output Set: N:\CRF4\08112004\I647457D.raw

298 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in

elevated 299

levels in body fluids of schizophrenic patients

301 <400> SEQUENCE: 15

303 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys

RAW SEQUENCE LISTING ERROR SUMMARY

DATE: 08/11/2004

PATENT APPLICATION: US/09/647,457D

TIME: 16:12:09

Input Set : A:\1276302-3corrected.ST25.txt Output Set: N:\CRF4\08112004\1647457D.raw

## Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/647,457D

DATE: 08/11/2004 TIME: 16:12:09

Input Set : A:\1276302-3corrected.ST25.txt
Output Set: N:\CRF4\08112004\1647457D.raw

```
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:38 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:39 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:40 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:41 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:42 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:42 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:43 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:44 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:45 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:46 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:58 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
```